Scantox Partners with Patholytix to Advance Digital Pathology Capabilities for GLP Studies
We are pleased to announce a new partnership with Patholytix, a leading provider of digital pathology solutions, marking an important step in our continued commitment to innovation and operational excellence in preclinical research.
Through this collaboration, our pathologists will be able to receive and evaluate digitally scanned histopathology slides for GLP studies, eliminating the need for physical slide shipment and enabling a more streamlined and efficient review process. Digital pathology provides faster access to study materials, greater flexibility for pathologists, and improved collaboration across locations, ultimately supporting faster study turnaround times for our clients.
The Patholytix platform has already been adopted by many of the world’s leading Contract Research Organizations (CROs), demonstrating its value and reliability in regulated research environments.
Implementation activities are already underway, and we expect the system to be fully validated for GLP use by January 2027. Once validation is complete, our clients will benefit from a fully digital pathology workflow that enhances both efficiency and accessibility while maintaining the highest quality standards.
This partnership reflects our commitment to investing in technologies that improve scientific evaluation, accelerate decision-making, and deliver greater value to our clients.
We look forward to sharing further updates as we progress toward full validation and deployment.
